ALK and neoplasm: Regarding the tumor-suppressor gene, Wang et al. (20) had previously reported that 38.1% of patients (8/22) with ALK rearrangement NSCLC had TP53 mutations, which reduced responsiveness to crizotinib and worsened the prognosis.